Sigyn Therapeutics, Inc. (SIGY)
USD 4.15
(0.0%)
USD 4.15
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -8856.00 USD | 15.29% |
| 2022 | -10.45 Thousand USD | -1850.2% |
| 2021 | -536.05 USD | 95.26% |
| 2020 | -11.3 Thousand USD | -110.5% |
| 2019 | 107.65 Thousand USD | 477.68% |
| 2018 | 18.63 Thousand USD | -97.59% |
| 2017 | 771.79 Thousand USD | 0.11% |
| 2016 | 770.91 Thousand USD | 3899.16% |
| 2015 | 19.27 Thousand USD | 7.67% |
| 2014 | 17.9 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -1523.00 USD | -111.82% |
| 2024 Q2 | -1364.00 USD | 10.44% |
| 2023 Q2 | -2615.00 USD | 0.0% |
| 2023 Q1 | -2615.00 USD | 0.0% |
| 2023 FY | -8856.00 USD | 15.29% |
| 2023 Q4 | 12.88 Thousand USD | 738.99% |
| 2023 Q3 | -2016.00 USD | 22.91% |
| 2022 Q3 | -2616.00 USD | 0.11% |
| 2022 Q4 | -2615.00 USD | 0.04% |
| 2022 FY | -10.45 Thousand USD | -1850.2% |
| 2022 Q1 | -2604.00 USD | -1.44% |
| 2022 Q2 | -2619.00 USD | -0.58% |
| 2021 FY | -536.05 USD | 95.26% |
| 2021 Q3 | -1332.00 USD | 70.76% |
| 2021 Q1 | - USD | 100.0% |
| 2021 Q2 | -4555.00 USD | 0.0% |
| 2021 Q4 | -2567.00 USD | -92.72% |
| 2020 FY | -11.3 Thousand USD | -110.5% |
| 2020 Q1 | 493.00 USD | -86.9% |
| 2020 Q3 | 2035.00 USD | 0.0% |
| 2020 Q2 | - USD | -100.0% |
| 2020 Q4 | -2528.00 USD | -224.23% |
| 2019 Q2 | 47.49 Thousand USD | 47.04% |
| 2019 Q1 | 32.3 Thousand USD | 109.08% |
| 2019 FY | 107.65 Thousand USD | 477.68% |
| 2019 Q4 | 3764.00 USD | -84.38% |
| 2019 Q3 | 24.09 Thousand USD | -49.28% |
| 2018 Q3 | 77.79 Thousand USD | -26.56% |
| 2018 Q4 | -355.75 Thousand USD | -557.32% |
| 2018 Q1 | 190.7 Thousand USD | 3.66% |
| 2018 Q2 | 105.92 Thousand USD | -44.45% |
| 2018 FY | 18.63 Thousand USD | -97.59% |
| 2017 Q2 | 247.26 Thousand USD | 28.16% |
| 2017 FY | 771.79 Thousand USD | 0.11% |
| 2017 Q4 | 183.96 Thousand USD | 16.8% |
| 2017 Q3 | 157.51 Thousand USD | -36.3% |
| 2017 Q1 | 192.92 Thousand USD | -89.54% |
| 2016 Q4 | 1.84 Million USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q1 | - USD | -100.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 FY | 770.91 Thousand USD | 3899.16% |
| 2015 Q1 | 7767.00 USD | 192.77% |
| 2015 Q4 | 1.00 USD | 0.0% |
| 2015 FY | 19.27 Thousand USD | 7.67% |
| 2015 Q3 | - USD | -100.0% |
| 2015 Q2 | 11.5 Thousand USD | 48.18% |
| 2014 Q3 | 8775.00 USD | 0.0% |
| 2014 FY | 17.9 Thousand USD | 0.0% |
| 2014 Q4 | -8372.00 USD | -195.41% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | -263.1% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 100.076% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 97.228% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.007% |
| Qrons Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 99.966% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 81.649% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 92.872% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 100.059% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 385.493% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 100.09% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 113.474% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 74.067% |
| Mesoblast Limited | -35.16 Million USD | 99.975% |
| Marizyme, Inc. | 457.7 Thousand USD | 101.935% |
| Genus plc | 178.7 Million USD | 100.005% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.004% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 114.232% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 102.159% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 19.491% |
| ContraFect Corporation | -154 Thousand USD | 94.249% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 82.288% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 111.537% |
| IMV Inc. | -962.29 Thousand USD | 99.08% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 97.715% |
| MultiCell Technologies, Inc. | 49.32 USD | 18056.204% |
| ONE Bio Corp. | 20.12 Million USD | 100.044% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.022% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 118.11% |
| Q BioMed Inc. | -8988.00 USD | 1.469% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 100.031% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 42.583% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.02% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 99.224% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 112.651% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -78.837% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 106.303% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 90.918% |
| GB Sciences, Inc. | -624.00 USD | -1319.231% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 89.706% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -4157.692% |
| Enzolytics Inc. | 30.7 Thousand USD | 128.839% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 101.836% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.001% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 98.279% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 101.434% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.002% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 89.438% |
| Kadimastem Ltd | -630.13 Thousand USD | 98.595% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 100.896% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 100.092% |
| BioStem Technologies, Inc. | 15.42 Million USD | 100.057% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 25.171% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 105.016% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 105.016% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 100.653% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 69.462% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 101.968% |
| SYBLEU INC | 11.69 Thousand USD | 175.718% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 100.192% |
| Bioxytran, Inc. | -8285.00 USD | -6.892% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 97.626% |
| Neutra Corp. | 14.33 Thousand USD | 161.779% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 89.2% |
| PureTech Health plc | -1.6 Million USD | 99.448% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 99.115% |
| IXICO plc | 3.27 Million USD | 100.271% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 98.724% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 99.506% |
| CSL Limited | 7.7 Billion USD | 100.0% |
| Cellectis S.A. | 18 Thousand USD | 149.2% |